These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 1823970)

  • 1. Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia.
    Atchley E; Weis TM; Derkach A; Galera PK; Xiao W; Glass J; DeWolf S; Roshal M; Shah R; Stump SE
    Leuk Res; 2023 Jul; 130():107311. PubMed ID: 37182399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia.
    Cerchione C; Martinelli G; Pedatella S; De Nisco M; Pugliese N; Manfra M; Marra N; Ronconi S; De Giorgi U; Altini M; Simonetti G; Di Rorà AGL; Bravaccini S; Catalano L; Dora Iula V; Pagano F; Picardi M; Bolognese A; Pane F; Martinelli V
    Anticancer Drugs; 2020 Jan; 31(1):67-72. PubMed ID: 31633499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines.
    Sklarz LM; Gladbach YS; Ernst M; Hamed M; Roolf C; Sender S; Beck J; Schütz E; Fischer S; Struckmann S; Junghanss C; Fuellen G; Murua Escobar H
    Cancer Cell Int; 2020; 20():390. PubMed ID: 32817744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.
    Stroet A; Hemmelmann C; Starck M; Zettl U; Dörr J; Friedemann P; Flachenecker P; Fleischer V; Zipp F; Nückel H; Kieseier BC; Ziegler A; Gold R; Chan A
    Ther Adv Neurol Disord; 2012 Mar; 5(2):75-9. PubMed ID: 22435072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
    Dennis M; Copland M; Kaur H; Kell J; Nikolousis E; Mehta P; Palanicawandar R; Potter V; Raj K; Thomas I; Wilson A
    Br J Haematol; 2022 Oct; 199(2):205-221. PubMed ID: 36000944
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
    Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy of relapsed AML and ALL].
    Nishikawa K
    Rinsho Ketsueki; 1996 Aug; 37(8):647-50. PubMed ID: 8827871
    [No Abstract]   [Full Text] [Related]  

  • 8. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
    Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
    Mariańska B; Apel D; Seferyńska I; Maj S
    Wiad Lek; 1998; 51(1-2):42-5. PubMed ID: 9608830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary results of the treatment of acute leukemia with mitoxantrone].
    Rozmysłowicz T; Pałynyczko G; Mazur J; Konecki R; Apel D; Mariańska B; Maj S; Hołowiecki J; Rudzka E; Lawniczek T
    Acta Haematol Pol; 1991; 22(1):69-81. PubMed ID: 1823970
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.